Saturday, February 25, 2017
Video: Page (1) of 1 - 04/12/11 Email this story to a friend. email article Print this page (Article printing at page facebook
Pharma News: Teva, Durect

By DMO Affiliate
Teva Pharmaceutical Industries (TEVA) and Active Biotech said today a 2-year, Phase 3 study of its multiple sclerosis drug laquinimod showed a statistically significant, 23% reduction in the rate of relapse, which was the studys primary endpoint. The stud
Pharma News: Teva, Durect

Page: 1


Our Privacy Policy --- About The U.S. Daily News - Contact Us - Advertise With Us - Privacy Guidelines